344 related articles for article (PubMed ID: 18929039)
21. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
22. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
Choi WH; Yoo IR; O JH; Kim SH; Chung SK
Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
[TBL] [Abstract][Full Text] [Related]
23. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
Koolen BB; van der Leij F; Vogel WV; Rutgers EJ; Vrancken Peeters MJ; Elkhuizen PH; Valdés Olmos RA
Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
[TBL] [Abstract][Full Text] [Related]
24. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
25. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Matsunaga N
Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249
[TBL] [Abstract][Full Text] [Related]
26. Standardized uptake value of ¹⁸F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden.
Ahn SG; Park JT; Lee HM; Lee HW; Jeon TJ; Han K; Lee SA; Dong SM; Ryu YH; Son EJ; Jeong J
Breast Cancer Res; 2014; 16(6):502. PubMed ID: 25551703
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Percentage Change in Metabolic Parameters as Measured by Dual-Time Point
Yoo J; Yoon HJ; Kim BS
J Womens Health (Larchmt); 2017 Oct; 26(10):1131-1137. PubMed ID: 28498790
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
29. Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.
Bertagna F; Evangelista L; Piccardo A; Bertoli M; Bosio G; Giubbini R; Orlando E; Treglia G
Rev Esp Med Nucl Imagen Mol; 2015; 34(1):24-9. PubMed ID: 25312053
[TBL] [Abstract][Full Text] [Related]
30. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
31. Variations in (18)F-FDG uptake in breast cancer depending on PET/CT acquisition position.
Lee JH; Jeon TJ; Ahn SG; Jeong J; Seok JW; Ryu YH
Clin Radiol; 2016 Jan; 71(1):86-91. PubMed ID: 26646369
[TBL] [Abstract][Full Text] [Related]
32. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma.
Ekmekcioglu O; Aliyev A; Yilmaz S; Arslan E; Kaya R; Kocael P; Erkan ME; Halac M; Sonmezoglu K
Nucl Med Commun; 2013 Nov; 34(11):1055-67. PubMed ID: 24025919
[TBL] [Abstract][Full Text] [Related]
33. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of SUV
Diao W; Tian F; Jia Z
Eur J Radiol; 2018 Aug; 105():1-7. PubMed ID: 30017264
[TBL] [Abstract][Full Text] [Related]
37. Is (18)F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?
Orevi M; Freedman N; Tahover E; Uziely B; Chisin R; Peretz T; Klein M
Acta Oncol; 2016; 55(2):244-7. PubMed ID: 26106853
[No Abstract] [Full Text] [Related]
38. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast.
Byun BH; Noh WC; Lim I; Lee SS; Cho AR; Park JA; Kim KM; Kim HA; Kim EK; Kim BI; Choi CW; Lim SM
Ann Nucl Med; 2013 Oct; 27(8):720-8. PubMed ID: 23700260
[TBL] [Abstract][Full Text] [Related]
39. Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.
Fujii T; Yajima R; Kurozumi S; Higuchi T; Obayashi S; Tokiniwa H; Nagaoka R; Takata D; Horiguchi J; Kuwano H
Anticancer Res; 2016 Oct; 36(10):5481-5485. PubMed ID: 27798919
[TBL] [Abstract][Full Text] [Related]
40. Prospective Clinical Trial of
Ulaner GA; Goldman DA; Corben A; Lyashchenko SK; Gönen M; Lewis JS; Dickler M
J Nucl Med; 2017 Jul; 58(7):1037-1042. PubMed ID: 27856630
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]